Expert Consultations: Real-World Answers

Medicinal Cannabis and the Psychiatric Patient: Clinical Harm vs Novel Treatment – Interview

Published on October 1, 2022 Certification expiration date: October 1, 2028

Guest

Wegdan Rashad

To unlock this audio you need to become a Silver, Gold, Silver extended or Gold extended Member.

Check Our CME Program

Downloads for Offline Access

Download Audio File (MP3)

Interview Highlights

Approximately 1.5% of cannabis users have a heart attack. Patients who use cannabis should be advised to take symptoms of chest pain or pressure seriously and get medical help should these occur.
Patients at risk for suicide must be asked about symptoms of depression as well as possible drug use, including cannabis use. Cannabis use can increase impulsivity and the risk for completed suicide.

Text Version

This edition of Psychopharmacology Institute’s Expert Consultations features Diana Martinez, M.D., a psychiatrist from the Columbia University Medical Center, Department of Psychiatry, Division of Substance Use Disorders. In this interview, we will discuss medicinal cannabis and the psychiatric patient.

Wegdan Rashad, M.D.: Today’s topic, which is medicinal cannabis and the psychiatric patient—clinical harm vs novel

Unlock this Expert Consultation and earn 0.50 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.

Get Instant Access

Already have an account? Sign in

Learning Objectives:

After completing this activity, the learner will be able to:

Recognize the importance of screening for at-risk cannabis use and cannabis use disorder among patients with psychiatric disorders.
Discuss relevant research on the potential risks and benefits of cannabis for the management of various psychiatric disorders.

Original Release Date: October 1, 2022

Review and Re-release Date: October 1, 2025

Expiration Date: October 1, 2028

Expert: Diana Martinez, M.D.

Medical Editors: Wegdan Rashad, M.D., Melissa Mariano, M.D.

Relevant Financial Disclosures:

None of the faculty, planners, and reviewers for this educational activity have relevant financial relationships to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

View the required educational content provided on this course page.
Answer the quiz for promoting retention of knowledge.
Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Diana Martinez, M.D.